Ingredion Tate & Lyle deal: overview
- Ingredion agrees to acquire Tate & Lyle to expand speciality ingredient capabilities
- The company’s portfolios are complementary, spanning starches, texture, fibre and sweeteners
- Deal would strengthen Ingredion’s margins, customer relationships and long-term growth
- Tate & Lyle would gain scale, reach and capital through combined platform
- Integration challenges and regulatory scrutiny remain before expected mutual benefits
A little over a week ago, ingredients majors Tate & Lyle and Ingredion agreed a £2.7bn deal.
If the deal goes through, two of the most significant players in ingredients will become one.
What are the benefits of such a deal for the two companies? If they become a whole, how would their parts complement each other?
Are the two companies compatible?
Any merger rests on compatibility. How compatible is Tate & Lyle with Ingredion?
Tate & Lyle’s portfolio is “fairly complementary” with Ingredion’s, says Seth Goldstein, senior equity analyst at investment research company Morningstar.
Its focus on mouthfeel ingredients complements Ingredion’s speciality texturisers, he says, and its focus on fibre fortification complements Ingredion’s plant-based offerings.
Tate & Lyle’s alternative sweetener portfolio will also help Ingredion grow in this ingredient category.
Filiberto Amati, advisor at FMCG consultancy Amati and Associates, agrees. The two companies possess “genuine complementarity“: while Ingredion brings strength in starches and plant-based components, Tate & Lyle is strong in texture, mouthfeel and sugar reduction.
“Together, they offer a formulation platform that no one could build independently within any reasonable timeframe. That breadth is what large food manufacturers want.”
They are also compatible from a geographic perspective. “Ingredion has a strong presence in the Americas, supported by its manufacturing footprint and customer base, whereas Tate & Lyle benefits from more established relationships and market strength in Europe,” explains Antonella Lisella, project manager in food and nutrition at B2B market insights and advisory, Kline and Company.
“This regional complementarity would enhance overall market coverage and improve access to multinational customers, particularly for Ingredion in Europe, where its position is comparatively weaker.”
The advantages for Ingredion
The deal significantly expands the capability of Ingredion, giving it access to a broader ingredient portfolio.
“Ingredion is acquiring capability, not scale,” says Amati and Associates’ Amati. The company has traditionally been present in commodities such as starches, sweeteners and plant-based components; the acquisition of Tate & Lyle offers it formulation capability, specifically in texture, mouthfeel and sugar reduction.
Tate & Lyle’s stabilisers, fibre and functional sweeteners are “the main attraction” of the deal, according to Amati. “Acquiring these strengthens Ingredion’s customer relationships, margins, and contract lengths, raising its growth ceiling beyond commodities.”
Bringing on board Tate & Lyle’s texture portfolio in particular has strong benefits for Ingredion.
“Texture is a consistent casualty of reformulation. When manufacturers reduce sugar, fat or calories, the product stops behaving as consumers expect it to. It thins. The mouthfeel changes.”
Tate & Lyle has spent years building the science to address this, he says, and after the merger will be able to provide Ingredion with capabilities that go “beyond ingredient substitution into sensory performance”.
The acquisition would bolster Ingredion’s position in the market. “Ingredion’s purchase of Tate & Lyle is designed to increase the buyer’s global reach and also its product range in the area of specialist ingredients, as it seeks to defend and augment its position in a competitive marketplace,” says Russ Mould, investment director at investment platform AJ Bell.
Tate & Lyle’s position
The benefit for Ingredion is clear; what about for Tate & Lyle?
From a strategic perspective, it makes sense for Tate & Lyle to agree to the deal, says Amati.
“Tate & Lyle has spent the last decade exiting commodity operations and repositioning as a speciality solutions business. That work has been successful.
“But competing at scale as a standalone speciality player demands capital and customer reach that are difficult to build organically.”
Tate & Lyle’s position within Ingredion’s broader platform would allow it to reach more customers faster, he argues.
Before the deal, Tate & Lyle’s share price had reached a low not seen since 2009. This, according to AJ Bell’s Mould, left the company “exposed” to the deal. Ingredion’s bid “looks shrewdly timed”, he says.
When the deal was announced, the share price shot back up.
The future
The deal has been agreed, but a complex process lies ahead. It must be approved by regulators before it can be finalised.
As the two companies occupy key positions in the ingredients market, the deal will require significant scrutiny.
The merger will not necessarily be easy. “Integration will be challenging because of both companies’ distinct cultures and client bases,” says Amati.
Yet if it does go through, analysts suggest, the deal will be beneficial for both companies involved.
Ingredion was contacted for comment. Tate & Lyle declined to comment.
